Quantcast

Latest Prostate cancer Stories

2014-06-02 08:29:12

Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma PETACH TIKVA, Israel, June 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced...

Cancer Survivor Numbers To Increase Over The Next Ten Years
2014-06-02 05:18:11

redOrbit Staff & Wire Reports - Your Universe Online With US cancer incidence rates in the midst of a 10-year decline, survivorship rates are on the rise, according to revised statistics released Sunday by the American Cancer Society. Currently, there are an estimated 14.5 million cancer survivors in the US, but that number is expected to rise to nearly 19 million by 2024, researchers from the organization reported in the June 1 edition of CA: A Cancer Journal for Clinicians....

2014-06-01 12:20:16

Diagnostic insights into gene mutations in solid tumor cancers will aid therapy selection and prognosis for patients and advance research NEW YORK and MADISON, N.J., June 1, 2014 /PRNewswire/ -- Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into...

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...

2014-06-01 08:20:11

-Study appears in June 1 online edition- NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England Journal of Medicine of the results from the Phase 3 PREVAIL trial, an international, randomized, double-blind, placebo-controlled clinical study of enzalutamide. The study evaluated the benefit...

2014-05-31 08:20:48

Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology RARITAN, N.J., May 31, 2014 /PRNewswire/ -- Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of single-agent ibrutinib (IMBRUVICA(®)) suggest continued durable responses in patients with treatment-naive (TN) or relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to data...

2014-05-30 12:26:08

Blue Cure Foundation Leads Push for 100,000 Signatures HOUSTON, May 30, 2014 /PRNewswire-USNewswire/ -- The Blue Cure Foundation announces the launch of a nationwide campaign petitioning the President to light the White House blue for one night in recognition of September's Prostate Cancer Awareness Month. To heighten awareness of cancer prevention and healthy lifestyle choices, Blue Cure plans to collect 100,000 signatures on the White House petition site to create a tremendous...

2014-05-30 12:25:59

WASHINGTON, May 30, 2014 /PRNewswire-USNewswire/ -- LUGPA will celebrate June as the start of Men's Health Month, urging men to take control of their health by educating themselves on important health issues. "Studies show that men are more likely to avoid going to the doctor than women, leaving them at the mercy of an unimaginable number of diseases and conditions that could have been prevented or improved if only they had talked to their doctor," said Dr. Juan Reyna, president of...

2014-05-30 08:25:19

Validation Data on More Than 300 Patients to be Released at the 2014 American Society of Oncology (ASCO) Annual Meeting REDWOOD CITY, Calif., May 30, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, announced today that its premier product, Guardant360(TM) is now widely commercially available following recent successful introduction to early access partners....

2014-05-29 12:29:19

PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. inVentiv initially will work with Advaxis to develop clinical study protocols and will...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related